Duchenne Muscular Dystrophy – Pipeline Review, H2 2019 : ResearchByMarkets.com

Research By Markets adds Market Research Report - Duchenne Muscular Dystrophy – Pipeline Review, H2 2019 : ResearchByMarkets.com

For detailed information: https://www.researchbymarkets.com/report/duchenne-muscular-dystrophy-pipeline-review-h2-2019-452550.html

Duchenne Muscular Dystrophy – Pipeline Review, H2 2019

Summary

Duchenne Muscular Dystrophy – Pipeline Review, H2 2019, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights

Duchenne Muscular Dystrophy – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 4, 13, 8, 1, 51, 24 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 10 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
4D Molecular Therapeutics Inc
Advanced Medical Projects
Akashi Therapeutics Inc
Alpha Anomeric
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
Armgo Pharma Inc
Audentes Therapeutics Inc
AUM LifeTech Inc
Avidity Biosciences LLC
Axolo Pharma Inc
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
Biophytis SA
Capricor Therapeutics Inc
Cardero Therapeutics Inc
Catabasis Pharmaceuticals Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
Evox Therapeutics Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Hibernaid Inc
InnoBioscience LLC
Italfarmaco SpA
Keros Therapeutics Inc
LambdaGen Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
Myos Inc
MyoTherix Inc
NicOx SA
Nippon Shinyaku Co Ltd
Novartis AG
NS Pharma Inc
OliPass Corporation
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
RASRx LLC
ReveraGen BioPharma Inc
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Solid Biosciences Inc
SOM Biotech SL
Spinalcyte Llc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
Vertex Pharmaceuticals Inc
WAVE Life Sciences Ltd
Zata Pharmaceuticals Inc


For queries regarding this report: https://www.researchbymarkets.com/sample-request/452550

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.